Akèy › Kansè Poumon ki pa ti selil › Arkansas › Little Rock
Etid klinik pou Kansè Poumon ki pa ti selil nan Little Rock, AR
13 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Little Rock (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- University of Arkansas for Medical Sciences /ID# 272923, Little Rock
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Ap rekriteFaz 3
- UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060), Little Rock
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Ap rekriteFaz 2
- CARTI Cancer Center, Little Rock
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- CARTI, Little Rock
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Little Rock
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Research Site, Little Rock
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Ap rekriteFaz 3
- CARTI Cancer Center ( Site 0006), Little Rock
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- University of Arkansas for Medical Sciences, Little Rock
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- University of Arkansas, Little Rock
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Arkansas for Medical Sciences, Little Rock
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Arkansas for Medical Sciences, Little Rock
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- University of Arkansas for Medical Sciences, Little Rock
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Little Rock
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Little Rock
- Skizofreni19 etid
- Kansè (tout kalite)14 etid
- Twoub depresif majè14 etid
- Leksemi mieloïd egi13 etid
- Obèsite11 etid
- Kansè Endomèt10 etid
- Depresyon10 etid
- Dyabèt Tip 210 etid
- Kansè poumon9 etid
- Maladi kadyovaskilè9 etid
- Kansè vejik9 etid
- Ensifizyans kadyak9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.